Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More

On February 17, 2026, Rock Springs Capital Management disclosed a buy of 46,497 shares of Kymera Therapeutics (NASDAQ:KYMR), with the estimated transaction value at $3.14 million based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Rock Springs Capital Management LP increased its stake in Kymera Therapeutics by 46,497 shares. The estimated transaction value for the quarter was $3.14 million, based on the average closing ...